Marciniak MD, Hudson P, Edgell E, Gomez JC, Sacristan JA; Academy for Health Services Research and Health Policy. Meeting.

Abstr Acad Health Serv Res Health Policy Meet. 2001; 18: 39.

Global Economic Affairs, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, Phone: (317) 433-1455, Fax: (317) 433-0448, E-mail: mdybelm2@lilly.com

RESEARCH OBJECTIVE: To compare typical and atypical antipsychotics, as well as olanzapine and risperidone, along the following dimensions: clinical, functional, and humanistic outcomes.STUDY DESIGN: Data were collected on the clinical status of the patients using the Clinical Global Impression (CGI) severity scale, and on functional status using the EuroQol (EQ-5D). Measures were made at a baseline visit before starting the new treatment, after 3 months, and after 6 months of treatment. Those patients with complete CGI, GAF and EQ-5D data at baseline and after 6 months of treatment were analysed. Binomial logistic regression models were used to compare rates of response on significant improvement in clinical status (CGI) and significant improvements in functioning, while improvement in HRQOL was assessed as the change in the EQ-5D from baseline to endpoint via a linear regression model.POPULATION STUDIED: Data were collected on a total of 2953 patients diagnosed with schizophrenia and treated in an outpatient setting.PRINCIPAL FINDINGS: Patients treated with atypical antipsychotics were significantly (p<0.01) more likely to achieve a clinical response and demonstrate significant improvements in functioning (p<0.01) and HRQOL (p<0.01) when compared with patients treated with typical antipsychotics. Olanzapine patients achieved higher levels of functioning were more likely to achieve significant improvements in functioning compared to risperidone patients as measured by GAF (<0.05). In addition, olanzapine patients exhibited a trend toward improved HRQOL when compared to patients treated with risperidone as measured by the EQ-5D (p=0.11).CONCLUSIONS: Controlling for confounding factors, these findings from a naturalistic study support the positive impact of atypical antipsychotics, and olanzapine in particular, in outpatients suffering from schizophrenia.IMPLICATIONS FOR POLICY, DELIVERY, OR PRACTICE: Controlling for confounding factors, these findings from a naturalistic study support the positive impact of atypical antipsychotics, and olanzapine in particular, in outpatients suffering from schizophrenia.PRIMARY FUNDING SOURCE: Eli Lilly and Company

Publication Types:

• Meeting Abstracts

Keywords:

• Antipsychotic Agents
• Benzodiazepines
• Humans
• Prospective Studies
• Risperidone
• Schizophrenia
• Treatment Outcome
• olanzapine
• psychology
• hsrmtgs

Other ID:

• GWHSR0001451

UI: 102273126

From Meeting Abstracts